Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

18F-DCFPyL PET/CT in a Single Large Metastasis With Prostate-Specific Antigen Level of 856 ng/mL

Wondergem, Maurits MD, PhD*; Srbljin, Sandra MD; van der Zant, Friso M. MD, PhD*; Broos, Wouter A. M. MD*; Knol, Remco J. J. MD, PhD*

doi: 10.1097/RLU.0000000000002690
Interesting Images
Buy

Literature shows that prostate-specific membrane antigen (PSMA) PET/CT may detect biochemical recurrence of prostate cancer at low prostate-specific antigen (PSA) levels, including detection of oligometastatic disease and hence direct metastasis-directed therapy. Although it is generally accepted that higher PSA values indicate higher disease burden, few data are available on the relation between PSA levels and number of detected metastases on PSMA PET/CT. This report demonstrates a patient with high PSA levels (856 ng/mL) at time of biochemical recurrence that showed only 1 metastasis on PSMA PET/CT. Combined androgen deprivation therapy and radiation therapy resulted in a complete biochemical response.

From the *Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Alkmaar

Department of Nuclear Medicine, Zaans Medisch Centrum, Zaandam, the Netherlands.

Received for publication March 5, 2019; revision accepted May 19, 2019.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Maurits Wondergem, MD, PhD, Wilhelminalaan 12 1815 JD Alkmaar, the Netherlands. E-mail: M.wondergem@nwz.nl.

Online date: July 5, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.